FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

-	OMB APPRO	OVAL	
TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287	
	Estimated average burden		

	Check this box if no longer subject to
$\neg$	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(b).

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Horton Kenneth L						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]										able)	g Pers	10% Ov	vner	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 02/05/2013										below)	? & Chief	f Leg	below) al Officer		
130 WAVERLY ST.  (Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person					
CAMBR	IDGE M	ÍA .	02139								led by Mor	ed by More than One Reporting								
(City)	(S	tate)	(Zip)																	
		Tab	le I - Non	-Deriva	ative	e Se	curities	s Ac	quired,	Dis	posed o	f, or B	ene	ficiall	y Owned					
Date			2. Transa Date (Month/Da		ar)   I	2A. Deemed Execution Date, if any (Month/Day/Year)				ties Acquired (A) or d Of (D) (Instr. 3, 4 a			5. Amou Securitie Beneficia Owned F Reported	es Fori ally (D) Following (I) (I		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	Amount (A) or (D)		Price	Transact	saction(s) r. 3 and 4)			(111501.4)	
Common	Stock		02/05/2013 A 12,084 <sup>(1)</sup> A \$0.01 21,751					D												
		-	Table II - [ (								osed of, onverti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Tr	4. Transactio Code (Inst 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				C	ode	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or No of	umber						
Employee Stock Option (right to	\$45.11	02/05/2013			A		90,625		(2)	C	)2/04/2023	Commo Stock	n 9	0,625	\$0.00	90,625	5	D		

## **Explanation of Responses:**

## Remarks:

Omar White, Attorney-In-Fact 02/07/2013

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products

<sup>2.</sup> Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013.